China Cell Therapy Regulatory Dual Track

China cell therapy regulatory dual track is the source’s frame for how China handles parts of clinical cell-therapy exploration in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. The episode contrasts CAR-T as a drug-regulated product with hospital-based technology management and IIT-style investigator-initiated treatment or trials.

[[LiuCheng|刘诚]] says unified drug review through CDE-style standards is easier to reason about when [[CARTCellTherapy|CAR-T]] is treated as a drug. By contrast, technology management inside individual hospitals can vary in standards and execution. The episode describes China’s 818 order as a compromise: work limited to one hospital can be managed as a medical technology, while national commercial sale should move into drug regulation.

Key Claims

• China’s concentrated patient resources and top-hospital centralization can make clinical validation faster.
• IIT and hospital technology-management routes can speed exploration but also create uneven standards.
• The same regulatory flexibility that helps In Vivo CAR-T and other cell therapies move quickly can be misused by gray-market stem-cell or anti-aging claims.
• The source frames China and the United States as both in the first tier of CAR-T clinical development.

Connections

• CAR-T Cell Therapy, In Vivo CAR-T, and Ex Vivo CAR-T Manufacturing - regulated therapy routes.
• [[LiuCheng|刘诚]] and Eureka Therapeutics - source viewpoint and company context.
• Food and Drug Administration - U.S. regulatory contrast around CAR-T being treated as a drug.
• Online Healthcare Regulatory Boundary - adjacent Chinese healthcare-regulation branch where clearer boundaries shape business and patient safety.